Immunotherapy of multiple sclerosis:: Where are we?: Where should we go?

被引：60
|
作者：
Martin, R
Stürzebecher, CS
McFarland, HF
机构：
[1] NINDS, Neuroimmunol Branch, NIH, Bethesda, MD 20892 USA
[2] Schering AG, Clin Dev CNS, D-13342 Berlin, Germany
来源：
NATURE IMMUNOLOGY | 2001年 / 2卷 / 09期
关键词：
D O I：
10.1038/ni0901-785
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Differences in multiple sclerosis patient's disease and their responses to standard drugs indicate that today's therapies need to be more individualized. It is proposed that gene expression profiling in conjunction with magnetic resonance imaging be used to optimize future treatment approaches.
引用
下载
收藏
页码：785 / 788
页数：4
相关论文
共 50 条
  • [41] Stress urinary incontinence: Where are we now, where should we go?
    DeLancey, JOL
    AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1996, 175 (02) : 311 - 319
  • [42] Personalized medicine and healthcare: where are we now, where should we go?
    Laszlo, Gulacsi
    Szabolcs, Bekassy
    Nora, Bittner
    Judit, Feith Helga
    Andrea, Ficzere
    Lajos, Horvath
    Zsolt, Horvath
    Ico, Toth
    Zsombor, Zrubka
    Erika, Toth
    Gabor, Kovacs L.
    ORVOSI HETILAP, 2023, 164 (06) : 202 - 209
  • [43] CHEST PAIN OF ESOPHAGEAL ORIGIN - WHERE ARE WE, AND WHERE SHOULD WE GO
    BENJAMIN, SB
    CASTELL, DO
    ARCHIVES OF INTERNAL MEDICINE, 1983, 143 (04) : 772 - 776
  • [44] Pheochromocytoma - where are we? Where should we go? A medical and scientific odyssey
    Neumann, HPH
    Opocher, G
    Januszewicz, A
    Eng, C
    FAMILIAL CANCER, 2005, 4 (01) : 1 - 1
  • [45] Pheochromocytoma – where are we? Where should we go? A medical and scientific odysseyReview
    Hartmut P. H. Neumann
    Giuseppe Opocher
    Andrzej Januszewicz
    Charis Eng
    Familial Cancer, 2005, 4 : 1 - 1
  • [46] Catfish Sampling Techniques: Where We Are Now and Where We Should Go
    Bodine, Kristopher A.
    Shoup, Daniel E.
    Olive, Jason
    Ford, Zachary L.
    Krogman, Rebecca
    Stubbs, Tyler J.
    FISHERIES, 2013, 38 (12) : 529 - 546
  • [47] Dissemination research in cancer control: where are we and where should we go?
    Deborah J. Bowen
    Glorian Sorensen
    Bryan J. Weiner
    Marci Campbell
    Karen Emmons
    Cathy Melvin
    Cancer Causes & Control, 2009, 20 : 473 - 485
  • [48] Digital human resource development: where are we? Where should we go and how do we go there?
    Thite, Mohan
    HUMAN RESOURCE DEVELOPMENT INTERNATIONAL, 2022, 25 (01) : 87 - 103
  • [49] Immunotherapy of Type 1 Diabetes: Where Are We and Where Should We Be Going?
    Luo, Xunrong
    Herold, Kevan C.
    Miller, Stephen D.
    IMMUNITY, 2010, 32 (04) : 488 - 499
  • [50] Where we should be and where we are
    Corral De la Calle, M. A.
    RADIOLOGIA, 2010, 52 (03): : 193 - 195
12345